Transcatheter tricuspid heart valve repair device developer 4Tech said today it tapped former Thoratec interventional products GM Dr. Michael Ennen as its new prez & CEO, taking over for Carine Schorochoff who will stay on as an advisor and board observer.
Dr. Ennen worked with with Thoratec to take the company’s 1st catheter-based product through CE Mark approval in the European Union and commercialization in the region, as well as helping initiate an investigational device exemption trial for the device in the U.S.
“I’m delighted to welcome Mike to 4Tech as President and CEO. His track record of rapidly advancing breakthrough technologies, combined with his commercial experience, make him an ideal fit for the company. Mike brings deep cardiovascular expertise to the role, as well as tremendous leadership, insight and passion, which we are confident will help drive the success of the TriCinch System and the broader company. I also want to thank Carine for leading 4Tech into the strong clinical-stage position the company is in today and look forward to working with her as an advisor and a board observer,” board chair Bill Hawkins said in prepared remarks.
Prior to his time with Thoratec, Dr. Ennen served as chief scientific officer and held VP roles at ev3/Covidien and FoxHollow Technologies, 4Tech said.
“I am honored to be joining 4Tech, which I believe is positioned to create the category-defining percutaneous solution for tricuspid valve disease. 4Tech has advanced an innovative repair technology, and I am excited to build on that foundation and to accelerate our development efforts. Tricuspid regurgitation remains a significant unmet need, and I’m confident that the TriCinch System will meaningfully advance the portfolio of structural heart products and help patients worldwide,” Dr. Ennen said in a press release.
“This is the perfect time in the evolution of 4Tech for Mike to become its next President and CEO. Mike has consistently demonstrated a superior ability to amplify the commercial viability of medical technology. The 4Tech Team is looking forward to continuing to deliver on 4Tech’s mission under Mike’s leadership and is keen to welcome him and his family to Galway,” former-CEO Schorochoff said in a prepared statement.
Integra LifeSciences (NSDQ:IART) today announced a number of new appointments, lifting Robert Davis Jr. as orthopedics & tissue tech prez and corporate VP, tapping Dan Reuvers as corp VP and SSS prez and announcing that Glen Coleman will assume oversight of its international biz.
“These key leadership appointments reflect the depth and strength of our management team, enabling us to promote executives from within the company. Bob, Dan and Glenn are proven leaders who have demonstrated exemplary management capabilities over the years and a track record of accomplishments that have contributed to our strong business performance,” Peter Arduini said in a prepared statement.
SuperSonic Imagine said late last month it tapped Michèle Lesieur as its new prez & CEO, replacing Bernard Doorenbos. Lesieur previously held various positions at Royal Philips (NYSE:PHG), including Philips France prez.
“SuperSonic Imagine’s supervisory board is enthusiastic about Michèle Lesieur becoming the company’s President and CEO. Her expertise, her leadership and her significant experience in international healthcare companies made her the best candidate to run SuperSonic Imagine, thus replacing Bernard Doorenbos, who was interim President and CEO. Indeed, we would like to thank Bernard for his contribution. Under Michèle’s experienced leadership, the company will continue to implement its strategic plan, which consists in moving forward on its various markets by capitalizing on the highly-innovative nature of its Aixplorer ultrasound platform, launching new innovative features and products and developing new fruitful partnerships. Along with our dedicated employees and a strong leadership team now headed by Michèle Lesieur, the Supervisory Board is confident that the scene is set for resuming a strong development track going forward,” board chair Michael Brock said in a press release.
Skyline Medical said last week it tapped former exec chair Dr. Carl Schwartz as its new chief executive officer.
“I am very pleased to be assuming the CEO position at this exciting inflection point in Skyline Medical’s strategic plan. We have made a great deal of progress in recent weeks with the Streamway System, including new domestic sales, the approval by Health Canada and the expansion of our global distribution network. We expect to receive CE Mark for Streamway in the coming weeks, and have engaged GLG Pharma for distribution in the U.K. and Central Europe. With the promise of using Streamway for patient diagnostics and a joint venture directed at mobile operating rooms and other U.S. government purchasers, our growth prospects are better than they have been in a very long time. I look forward to executing our business plan with the support of a talented management team and of our board of directors,” Dr. Schwartz said in a prepared statement.
The post Tricuspid repair firm 4Tech names Thoratec vet Ennen as CEO | Personnel Moves December 5, 2016 appeared first on MassDevice.
from MassDevice http://ift.tt/2gV5aLe
Cap comentari:
Publica un comentari a l'entrada